why choose us

First received: February 08, 2023

Clinical Trial: An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases

Study Status: Completed

Recruit Status: RECRUITING

Condition: Lupus Nephritis

Study Type: INTERVENTIONAL


Official Title: An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Gl

Brief Summary: The goal of this clinical study is to evaluate multiple dose levels of povetacicept (ALPN-303) in adults with immunoglobulin A (IgA) nephropathy, membranous nephropathy, or lupus-related kidney disease (lupus nephritis) to determine if povetacicept is safe and potentially beneficial in treating these diseases.During the study treatment period, participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month study treatment extension period.

Read more